Name (Synonyms) | Correlation | |
---|---|---|
drug599 | Cognitive behavioral therapy (CBT) Wiki | 1.00 |
drug2783 | computerized cognitive training (CCT) Wiki | 1.00 |
drug371 | Blood collection on admission and longitudinally Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viral pneumopathy that can progress to acute respiratory distress syndrome (ARDS). The host-pathogen relationships and the physiopathological mechanisms underlying the clinical aggravation of COVID-19 patients remain misunderstood. The project aim is to create a prospective cohort of biological samples collected from well characterized COVID-19 patients. This project aims first to identify based on these samples an early immune signature predictive of clinical worsening of COVID-19 patients in order to improve their management, and secondarily to better understand pathophysiological mechanisms underlying the different phases of the disease in order to identify innovative therapeutic targets and vaccine perspectives.
Description: Analysis of the phenotypic profiling of blood T-cells by multicolor fluorescence-activated cell sorter (FACS) analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 0Description: Analysis on plasma samples of a wide range of cytokines and chemokines using multiplex
Measure: Dosage of cytokines and chemokines in plasma samples Time: Day 0Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 2Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 4Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 8Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 12Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers
Measure: Immune signature Time: Day 30 (or in discharge)Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 0Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 2Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 4Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 8Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 12Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin
Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity Time: Day 30 (or in discharge)